This page enables investors and potential investors alike to access core management and financial information in compliance with Rule 26 of the AIM Rules for Companies.
This information was last updated on 8 January 2025.
Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The Company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Faron Pharmaceutials’ ordinary shares of no par value are only admitted to trading on the AIM market of the London Stock Exchange and on issuing Nasdaq First North Growth Market.
Shareholders should note that the rights of shareholders in a company incorporated in Finland may be different from the rights of shareholders in a UK incorporated company.
Regulation of Takeover
The registered office of the Company is in Finland, a member state of the European Economic Area other than the United Kingdom and its shares are traded on AIM, which is not a regulated market for the purpose of the City Code on Takeovers and Mergers (the “UK Takeover Code”).
Accordingly, the Company is not subject to the UK Takeover Code. As the Company is neither subject to equivalent legislation in Finland the Company has voluntarily adopted certain provisions of the UK Takeover Code and these have been incorporated into its Articles of Association.
